Oncology Supplemental       

FOI REFERENCE: 24232     FOI DATE: 16^th July 2024     

Q1. Do you treat patients for Urothelial Cancer? Yes

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:  

• Atezolizumab (Tecentriq) *patients
• Avelumab (Bavencio) 8 patients
• Carboplatin single agent or in any other combination 11 patients
• Carboplatin with Gemcitabine 10 patients
• Carboplatin with Paclitaxel 0 patients
• Cisplatin single agent or in any other combination 9 patients
• Cisplatin with Gemcitabine 9 patients
• Cisplatin with Gemcitabine + Nivolumab (Opdivo) 0 patients
• Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) 0 patients
• Nivolumab (Opdivo) 0 patients
• Pembrolizumab (Keytruda) 0 patients
• Other active systemic anti-cancer therapy
• Palliative care only 23 patients

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part? Worcestershire Acute Hospital NHS Trust don’t have any trials in Urothelial cancer at present.

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:  

• Atezolizumab (Tecentriq)  12 patients
• Durvalumab (Imfinzi) * patients
• Nivolumab (Opdivo) * patients
• Pembrolizumab (Keytruda) 17 patients
• Chemotherapy 108 patients
• Radiotherapy 10 patients
• Chemotherapy AND Radiotherapy 7 patients